Quality assurance for nonradiographic radiotherapy localization and positioning systems: report of Task Group 147.

New technologies continue to be developed to improve the practice of radiation therapy. As several of these technologies have been implemented clinically, the Therapy Committee and the Quality Assurance and Outcomes Improvement Subcommittee of the American Association of Physicists in Medicine commissioned Task Group 147 to review the current nonradiographic technologies used for localization and tracking in radiotherapy. The specific charge of this task group was to make recommendations about the use of nonradiographic methods of localization, specifically; radiofrequency, infrared, laser, and video based patient localization and monitoring systems. The charge of this task group was to review the current use of these technologies and to write quality assurance guidelines for the use of these technologies in the clinical setting. Recommendations include testing of equipment for initial installation as well as ongoing quality assurance. As the equipment included in this task group continues to evolve, both in the type and sophistication of technology and in level of integration with treatment devices, some of the details of how one would conduct such testing will also continue to evolve. This task group, therefore, is focused on providing recommendations on the use of this equipment rather than on the equipment itself, and should be adaptable to each user's situation in helping develop a comprehensive quality assurance program.

Code of Ethics for the American Association of Physicists in Medicine: report of Task Group 109.

A comprehensive Code of Ethics for the members of the American Association of Physicists in Medicine (AAPM) is presented as the report of Task Group 109 which consolidates previous AAPM ethics policies into a unified document. The membership of the AAPM is increasingly diverse. Prior existing AAPM ethics polices were applicable specifically to medical physicists, and did not encompass other types of members such as health physicists, regulators, corporate affiliates, physicians, scientists, engineers, those in training, or other health care professionals. Prior AAPM ethics policies did not specifically address research, education, or business ethics. The Ethics Guidelines of this new Code of Ethics have four major sections: professional conduct, research ethics, education ethics, and business ethics. Some elements of each major section may be duplicated in other sections, so that readers interested in a particular aspect of the code do not need to read the entire document for all relevant information. The prior Complaint Procedure has also been incorporated into this Code of Ethics. This Code of Ethics (PP 24-A) replaces the following AAPM policies: Ethical Guidelines for Vacating a Position (PP 4-B); Ethical Guidelines for Reviewing the Work of Another Physicist (PP 5-C); Guidelines for Ethical Practice for Medical Physicists (PP 8-D); and Ethics Complaint Procedure (PP 21-A). The AAPM Board of Directors approved this Code or Ethics on July 31, 2008.

Characterization and clinical evaluation of a novel IMRT quality assurance system.

Intensity-modulated radiation therapy (IMRT) is a complex procedure that involves the delivery of complex intensity patterns from various gantry angles. Due to the complexity of the treatment plans, the standard-of-care is to perform measurement based patient-specific quality assurance (QA). IMRT QA is traditionally done with film for relative dose in a plane and an ion chamber for absolute dose. This is a laborious and time-consuming process. In this work, we characterized, commissioned, and evaluated the QA capabilities of a novel commercial IMRT device Delta4, (Scandidos, Uppsala, Sweden). This device consists of diode matrices in 2 orthogonal planes inserted in a cylindrical acrylic phantom that is 22 cm in diameter. Although the system has detectors in only 2 planes, it provides a novel interpolation algorithm that is capable of estimating doses at points where no detectors are present. Each diode is sampled per beam pulse so that the dose distribution can be evaluated on segment-by-segment, beam-by-beam, or as a composite plan from a single set of measurements. The end user can calibrate the system to perform absolute dosimetry eliminating the need for additional ion chamber measurements. The patient's IMRT plan is imported into the device over the hospital LAN and the results of measurements can be displayed as gamma profiles, distance-to-agreement maps, dose difference maps, or the measured dose distribution can be superimposed of the patient's anatomy to display an as-delivered plan. We evaluated the system's reproducibility, stability, pulse-rate dependence, dose-rate dependence, angular dependence, linearity of dose response and energy response using carefully planned measurements. We also validated the system's interpolation algorithm by measuring a complex dose distribution from an IMRT treatment. Several simple and complex isodose distributions planned using a treatment planning system were delivered to the QA device; the planned and measured dose distributions were then compared and analyzed. In addition, the dose distributions measured by conventional IMRT QA, which uses an ion chamber and film, were compared. We found that this device is accurate and reproducible and that its interpolation algorithm is valid. In addition the supplied software and network interface allow a streamlined IMRT QA process.

The management of imaging dose during image-guided radiotherapy: report of the AAPM Task Group 75.

Radiographic image guidance has emerged as the new paradigm for patient positioning, target localization, and external beam alignment in radiotherapy. Although widely varied in modality and method, all radiographic guidance techniques have one thing in common--they can give a significant radiation dose to the patient. As with all medical uses of ionizing radiation, the general view is that this exposure should be carefully managed. The philosophy for dose management adopted by the diagnostic imaging community is summarized by the acronym ALARA, i.e., as low as reasonably achievable. But unlike the general situation with diagnostic imaging and image-guided surgery, image-guided radiotherapy (IGRT) adds the imaging dose to an already high level of therapeutic radiation. There is furthermore an interplay between increased imaging and improved therapeutic dose conformity that suggests the possibility of optimizing rather than simply minimizing the imaging dose. For this reason, the management of imaging dose during radiotherapy is a different problem than its management during routine diagnostic or image-guided surgical procedures. The imaging dose received as part of a radiotherapy treatment has long been regarded as negligible and thus has been quantified in a fairly loose manner. On the other hand, radiation oncologists examine the therapy dose distribution in minute detail. The introduction of more intensive imaging procedures for IGRT now obligates the clinician to evaluate therapeutic and imaging doses in a more balanced manner. This task group is charged with addressing the issue of radiation dose delivered via image guidance techniques during radiotherapy. The group has developed this charge into three objectives: (1) Compile an overview of image-guidance techniques and their associated radiation dose levels, to provide the clinician using a particular set of image guidance techniques with enough data to estimate the total diagnostic dose for a specific treatment scenario, (2) identify ways to reduce the total imaging dose without sacrificing essential imaging information, and (3) recommend optimization strategies to trade off imaging dose with improvements in therapeutic dose delivery. The end goal is to enable the design of image guidance regimens that are as effective and efficient as possible.

Changes in some characteristics between the wild and Al-tolerant coffee (Coffea arabica L.) cell line.

An aluminium (Al)-tolerant cell line (LAMt) of coffee (Coffea arabica L.) was obtained from a cell suspension culture and biochemically and molecularly characterized in an MS medium at half ionic strength and low pH. LAMt grew 30% more than the control line (susceptible to Al) in the presence of different concentrations of Al, showed a lower free Al concentration in the medium and had higher phospholipase C specific activity (80%). Membrane integrity of the LAMt was 50% greater than the control line when both were incubated in the presence of different Al concentrations (measured by Evans Blue uptake). Finally, the use of microsatellite primers revealed no difference in the DNA pattern of both cell lines.

Anthropomorphic breast phantoms for quality assurance and dose verification.

An evaluation of two anthropomorphic breast phantoms, which have been designed for quality assurance and dose verification of radiotherapy treatment of breast cancer patients, is presented. These phantoms are identical in terms of their dimensions and shape, and composed of several layers of either Plastic Water or tissue-equivalent material. Both water- and tissue-equivalent phantoms include lung- and rib-equivalent components. The phantoms simulate large, medium and small breasts. The value of the phantoms as breast treatment quality assurance tools was assessed by dose measurements with ionization chamber and thermoluminescence dosimeters (TLD), at different points inside the phantom. Measurements were made by irradiating the phantoms under conditions representing the different treatment techniques, found by the Radiological Physics Center (RPC) during its dosimetry quality audits. Most irradiations were performed with the water-equivalent breast phantom. One experiment was performed under consistent irradiation conditions to compare the tissue-equivalent phantom with the water-equivalent phantom. Measurements were compared with the dose estimated by the RPC's manual calculations used to check clinical charts of patients entered in a National Surgical Adjuvant Breast and Bowel Project (NSABP) protocol. Measurements were also compared with isodose distributions generated by a commercial radiation treatment planning (RTP) system. In the homogeneous three-dimensional (3-D) phantom, fairly good agreement (within 5%) was observed at the NSABP dose prescription point between measurements and 2-D dose estimation by manual calculations. At the same dose prescription point, but located in the heterogeneous 3-D phantom, agreement between measurements and a 3-D RTP system was within about 3%. Manual calculation resulted in overestimation of up to 6%. The general agreement between the TLD measurements and the 2-D RTP values was within 3% at various off-axis points, with the exception of a few points far off-axis, near the high-dose gradient region at the surface of the phantom.